Renalytix AI ^{Priced, Nasdaq: RNLX}

We are an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary AI-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (EHR) systems, to generate a unique patient risk score, which . This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians to optimize the allocation of treatments and clinical resources to patients at highest risk. CKD affects approximately 37 million individuals in the US, significantly impacting their quality of life and resulting in Medicare spending of over $120 billion per year. We believe we are well-positioned to help meet an urgent medical need with KidneyIntelX, a laboratory developed test (LDT) which has been granted a common procedural terminology (CPT) code, national Medicare pricing, and a positive coverage determination from a regional, private physician-led health insurance payor. Further, it has been granted breakthrough device designation from the U.S. FDA. Building on these milestones, we believe our population health-based business model, which includes partnerships with healthcare systems such as Mount Sinai Health System, will help facilitate commercial adoption of KidneyIntelX in the US.